Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer

Fig. 2

The methylation status of ZMYND10 promoter in breast carcinoma a RT-PCR and MSP analysis of ZMYND10 mRNA expression and promoter methylation in breast cancer cell lines. Normal breast tissue samples were used as controls. b qPCR indicates demethylation by Aza and TSA (A+T) restored ZMYND10 expression in MDA-MB231and SK-BR-3 cells. c Representative methylation of ZMYND10 in breast tumor and normal tissues as examined by MSP. d Bisulfite genomic sequencing confirmed A+T treatment could inhibit the methylation of the ZMYND10 promoter. e The methylation status of the ZMYND10 promoter in breast cancer tissues was significantly higher than which in normal breast tissues. Aza, 5-aza-2′-deoxycytidine; BN, breast normal tissue; BF, breast fringe; BA, breast cancer adjacent tissues; M, methylated; U, unmethylated; MSP, methylation-specific polymerase chain reaction; RT-PCR, semiquantitative reverse transcription PCR

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us